Sushil Finance
ACTIONABLE KNOWLEDGE

Diwali Muhurat Pick 2026



INITIATING COVERAGE

Viyash Scientific Ltd.

November 05, 2026

Sushil Finance
ACTIONABLE KNOWLEDGE

HAPPY INNOVATION-WALI & CYBORG-ROUS NEW YEAR

BHARAT 2030



E



P



C


PER CAPITA GDP	AUTO, AC, TV, VC
URBANIZATION	GAMING, SHOES, WATCH, SMARTPHONES
C-C-C MOVE	HOME, QSR, CAR, BNPL
E-COMMERCE	QUICK COMMERCE, MARKETPLACE FOOD DELIVERY, OSA
GLOBALISATION & DIGITAL MARKETING	TRAVEL, EXPERIENCES CONCERTS, OTT

62373 2030 208950

I

AI	LLM, NLM, ML GENERATIVE AI
DATA CENTER	WIRE, CABLES, RAM POWER SYSTEMS
E R&D	SDB, EV, MEDICAL DEVICES, INDUSTRY 4.0, DIGITAL TWINS
PAYMENT	UPI, TAP & PAY, E-WALLET CRYPTO CURRENCY
DIGITIZATION	CLOUD, PROCESS AUTOMATION DATA ANALYTICS, DIGITAL IDENTITY

C$_H$



AXISCADES TANEJA
MARINE ELECTRICALS
WOCKHARDT SUVEN LIFE
ASTRA MICROWAVE
VENUS REM SHILPA MEDI

NEW ADMISSIONS



UNDER GRAD

FORCE MOTORS

DYNAMATIC TECHNOLOGIES

GRADUATION



POST GRAD

TAAL TECH

PLACEMENTS




HALL OF FAME

PATH BHAVYA AM DABHADE

Equities • Mutual Funds & IPO • Institutional & NRI Desk • Internet & Mobile Trading • SLBM • Depository Services

Sushil Financial Services Private Limited. Regd. Office - 12, Homji Street, Fort, Mumbai - 400 001 • Tel. No. +91-22-40936000. Member : BSE/ NSE SEBI Reg. No. - INZ000165135 Research Analyst – SEBI Reg. No. INH000000867 I RA related Disclaimer link: http://bit.ly/2F1Qc4b. DP (CDSL) SEBI Reg. No.- IN-DP-504-2020.
Investment in securities market are subject to market risks, read all the related documents carefully before investing.
www.sushilfinance.com I www.savashare.in



Sushil Finance®
ACTIONABLE KNOWLEDGE

INITIATING REPORT

VIYASH SCIENTIFIC LTD:

Science-Led Integration across API, Human Health, Animal Health & CDMO

Date: November 5, 2026

Analyst: Umesh Matkar

Viyash Scientific Ltd

Initiating Coverage

PHARMA

BUY

CMP Rs.232	TARGET Rs.314
Reuters Code	SEQU.BO
Bloomberg Code	VIYASH IN
BSE Code	512529
NSE Symbol	VIYASH
Face Value	Rs. 2
Market Cap.	Rs. 10,288 cr
52 Week H/L	Rs. 298 / 178
Shares Outstanding	44 cr.
Avg. Daily Vol. (6m)	3,625,980 Shares
Price Performance (%)	

1M	3M	6M
(1)	(14)	12

200 Days EMA Rs.234

SHARE HOLDING (%)

Promoters	49.2
FII	2.6
FI/MF	7.1
Body Corporates	6.2
Public & Others	34.9

SENIOR RESEARCH ANALYST

Umesh Matkar | +91 22 4093 4082

umeshm@sushilfinance.com

SALES:

Devang Shah | +91 22 4093 6060/61

devang.shah@sushilfinance.com

INDUSTRY DYNAMICS FAVORABLE FOR THE GROWTH

The most potent catalyst for the Indian CDMO sector is the implementation of the United States BIOSECURE Act. This legislation aims to restrict US entities from utilizing federal funds to procure biotechnology equipment or services from specific foreign adversarial companies, citing national security concerns. The Act explicitly targets prominent Chinese CDMOs and genomics firms, including WuXi AppTec, WuXi Biologics, BGI, MGI, and Complete Genomics. China currently commands a 30% to 35% share of the global API and CDMO market, representing roughly US$ 60 billion to US$ 75 billion in annual revenue. So even a fraction shift in the market share to India, should benefit the Indian companies.

Global pharmaceutical innovators and large generic conglomerates are under immense pressure to decouple their supply chains from Chinese manufacturers due to geopolitical tensions and environmental disruptions. By offering a fully localized, USFDA-compliant manufacturing ecosystem rooted in India, Viyash secures long-term, high-volume contracts by guaranteeing supply security to its partners

BACKWARD INTEGRATION AND PRODUCT AND GEOGRAPHIC EXPANSION TO DRIVE GROWTH

While near-term growth is supported by existing capacity, backward integration and volume optimization, the true structural inflection in Viyash's earnings profile is back-ended and tied to its complex R&D engine. The company has deliberately pivoted away from commoditized, high-volume generic APIs toward high-barrier, complex therapeutic areas such as oncology and central nervous system (CNS) treatments. Developing these highly potent active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs requires specialized containment infrastructure (OEB-4/5 levels) and a long gestation period, typically taking five to seven years from development to commercialization. The company has guided for a revenue of $1bn by 2032 and a $150-200 mn companion ambition for the long term with high potency API launches around 2029, while it is confident to achieve Rs.4000 cr in FY27, with improving margins due to focus on high potent APIs.


Y/E Mar	Revenue (Rs. Cr)	EBITDA (Rs. Cr)	EBITDA Margin (%)	APAT (Rs. Cr)	NPM (%)	AEPS (Rs.)	P/E (x)	P/Bv (x)
FY26	3,420.30	652.5	*19.1%*	224.7	*6.6%*	4.0	57.9	3.2
FY27E	3,931.90	743.1	*18.9%*	339.1	*8.6%*	7.8	29.8	2.9
FY28E	4,491.50	848.9	*18.9%*	387.4	*8.6%*	8.9	26.1	2.7
FY29E	5,138.40	991.7	*19.3%*	466.3	*9.1%*	10.7	21.6	2.4

OUTLOOK & VALUATION

We expect the company's topline to grow at a CAGR of ~15% to Rs. 5,138 cr in FY26-29E. On conservative basis, we have expected EBITDA margin to remain at healthy level, 19%. Hence, with an expected PAT margin of 9% in FY29E, we expect the PAT and EPS to be at Rs. 466 cr and Rs. 10.7 respectively. **We have assigned a P/E multiple of 30x to arrive at a price target of Rs. 314 which provides an upside of ~35% within 18 to 24 months from the current market price of Rs.232.**

COMPANY OVERVIEW

Carlyle-backed Viyash Scientific Ltd is an integrated global pharmaceutical company formed by the merger of Sequent Scientific, India's largest pure-play animal health company, with Viyash Life Sciences, creating a single listed entity spanning APIs, formulations and CDMO across more than 150 countries.



Source: Sushil Finance Research, Company Research

COMPANY OVERVIEW

SeQuent's line runs back to 1985. The company "originated as Visistha Trades, transitioned into a focused pharmaceutical and animal health company, and rebranded as SeQuent Scientific Limited. From 2014, it built the Alivira animal health brand and expanded across Europe, Latin America and emerging markets with USFDA veterinary API approvals, then spent 2020–2025 deepening its geographic and specialty footprint. Global private equity firm Carlyle took a majority stake in September 2020 and held ~53% as of March 2025.

Viyash is the newer strand. Dr Haribabu Bodepudi, a PhD in organic chemistry who spent ~20 years at Mylan rising to Global COO and CEO of Mylan India, founded Viyash Life Sciences in February 2019 alongside Dr Srihari Raju Kalidindi 56. It grew fast through acquisitions: Vindhya Pharma and Vandana Life Sciences in 2019–20, then in 2021 Mylan's API and formulation units in Vizag and Mumbai, a strategic Carlyle investment, and Symed Labs and Appco Pharma.

The merger that created today's company

Announced in September 2024: SeQuent and Viyash proposed a strategic merger to create "a global animal health leader with end-to-end integrated capabilities". The through-line is integration: a 1985-born animal health specialist and a 2019-born human pharma challenger, both Carlyle-backed, merged into one company that makes its own active ingredients, turns them into finished doses in its own plants, and sells them through its own distribution across four continents

Management quality

- **Dr. Haribabu Bodepudi: MD & Group CEO: PhD in Organic Chemistry,** with decades at Mylan, rising to CEO of Mylan India and Global COO of Mylan. He built Mylan's ARV business to over 50% market share.

- **Mr Rajaram Narayanan: Whole Time Director & CEO-Animal Health: MBA from IIFT Delhi, and an Advanced Management Program from Harvard Business School,** joined Sequent's board in April 2022, previously MD of Sanofi India, Chief Marketing Officer at Airtel, and 18 years at Hindustan Unilever building consumer brands across India and Asia.

Source: Sushil Finance Research, Company Research

Product Mix & Revenue Contribution

Viyash leverages shared research and development resources and manufacturing scale to drive substantial operating leverage. The business model is segmented into four primary, synergistic verticals.

The Human Active Pharmaceutical Ingredients (APIs) and Intermediates division represents the historical core and a continued growth engine. This division focuses on highly complex therapeutic areas including oncology, immunology, cardiovascular, central nervous system (CNS), and anti-infectives. Management has diverted from low-margin, high-volume commodity APIs, toward complex synthetic chemistry. The division's product pipeline features molecules targeting patent expiration cliffs between 2030 and 2040, positioning Viyash for "Day 1" commercial launches that capture peak generic pricing and maximize market share.

The Animal Health division, encompassing both Veterinary APIs and Formulations, originates from the legacy Sequent Scientific business and operates via the globally recognized 'Alivira' brand. While historical revenues in this segment were stagnant at approximately Rs.350cr annually for several years, recent strategic overhauls have resulted in a breakout to a >Rs.400 cr run rate. The formulation portfolio spans injectables, oral solutions, powders, and premixes, serving both production livestock (farm animals) and the rapidly expanding companion animal market across more than 100 countries.

The Custom Development & Manufacturing Services (CDMO/CRO) segment operates at the highest end of the value chain. Currently generating Rs.200 cr in annual revenue, this segment functions under three distinct engagement models: NCE (New Chemical Entity) development for innovators moving from Phase III clinical trials to commercialization; lifecycle management for post-patent innovator molecules; and specialty generic contract manufacturing for global pharmaceutical firms lacking complex in-house infrastructure. Backed by rigorous Intellectual Property (IP) protection protocols, specialized cytotoxic containment suites, and a flawless regulatory track record, Viyash commands deep client stickiness among top-tier global generic and innovator companies.

The Finished Dosage Formulations (FDF) division captures the final margin profile of the value chain. Viyash’s human formulation business is anchored by its US-based subsidiary, Appco Pharma LLC, which is supported by low-cost, vertically integrated API manufacturing in India. For Animal Health, the formulation manufacturing footprint is geographically decentralized across Spain, Turkey, and Brazil (with EU-GMP and local GMP certifications) to cater seamlessly to regional demands and facilitate rapid geographical extension of existing dossiers

Source: Sushil Finance Research, Company Research

INVESTMENT RATIONALE

Industry dynamics favorable for the growth

The global pharmaceutical industry is undergoing a structural change generating a multi year tailwinds for integrated Indian players possessing complex capabilities. The driving force for the change is the geopolitical push to de-risk supply chains away from the Chinese reliance, recently codified in the US BIOSECURE ACT. Global innovators and top-tier generic firms are aggressively auditing Indian CDMOs to secure alternative, compliant capacity. Viyash's flawless USFDA track record across 10 facilities makes it a primary beneficiary of this shift. Crucially, the manufacturing of OEB 4/5 cytotoxic compounds has historically been heavily concentrated in China; Viyash's dedicated Taloja and Vizag containment sites position the company to make the most of the opportunity.

Concurrently, the global pharmaceutical industry is facing an unprecedented "Patent Cliff" / Loss of Exclusivity (LOE) cycle, with hundreds of billions of dollars in branded drug revenues going off-patent between 2026 and 2030. Viyash's R&D engine is heavily geared toward this cliff. Management has confirmed that over 50% of their human API development pipeline consists of "First-to-File" or "Day 1 Launch" opportunities. The molecules are highly complex (mostly oncology and high potent drugs), where post patent price erosion is typically contained to 50-60% compared to 95% erosion witnessed in commoditized oral solid dosages

Global Animal Health Sector Trends

The global Animal Health market represents an approximately US$ 56 bn opportunity, structurally divided into livestock and companion animal segments. The livestock segment, commanding roughly 60% of the market, is driven by secular trends in global protein consumption, intensive farming practices, and stringent governmental mandates to prevent infectious disease outbreaks. The veterinary pharmaceutical sector is exhibiting secular, non-cyclical growth characteristics, primarily driven by the companion animals. Pet animal ownership has shot up post-Covid 19; Europe alone boasts over 186 million cats and dogs (94 million dogs and 92 million cats in the US market alone). While the human generic market is heavily saturated, generic penetration in the companion animal space remains nascent, hovering around a mere 15%. As pet populations grow and veterinary care costs rise against a backdrop of structurally low insurance coverage (only ~15% in Europe), consumers are being forced toward affordable generic alternatives. Viyash has presence in the animal API portfolio, is aggressively forward integrating this advantage into finished dosages to capture the entire value chain. Unlike human generics, animal health generics retain superior pricing power, often stabilizing at 60-70% of the innovator's original price, ensuring robust, long-tailed margin profiles

Source: Sushil Finance Research, Company Research

INVESTMENT RATIONALE

Backward and Product and Geographic expansion to drive growth

The company has established a formidable backward integration and chemistry moat. Through an aggressive network optimization strategy over the past two years, management has achieved greater than 85% backward integration across its key molecules, substantially reducing reliance on external Key Starting Materials (KSMs). This structural shift from raw material sourcing to in-house manufacturing severely insulates gross margins against generic price erosion and supply-chain volatility, a fact validated by the 321 basis point gross margin expansion observed in FY26. Annualized operational synergies of Rs.50-60 cr are already being realized through plant rationalization and corporate function consolidation, with management expecting this to scale toward Rs.125-150 cr over the next 12 to 18 months. Furthermore, the company's advanced chemistry capabilities—specifically its OEB 4/5 containment facilities for highly potent APIs (HPAPI) and cytotoxic compounds—create prohibitive barriers to entry. The technical complexity required to operate these facilities at scale secures Viyash's position as a preferred partner for global innovators facing complex chemistry challenges

Second, Viyash operates a de-risked, dual-engine business architecture that balances human health CDMO operations with a rapidly scaling animal health formulation business. The amalgamation of Viyash Life Sciences and Sequent Scientific, formalized via a National Company Law Tribunal (NCLT) order on November 18, 2025, has resulted in an integrated pharmaceutical powerhouse. The resulting entity, Viyash Scientific Ltd, is no longer a fragmented, commoditized Active Pharmaceutical Ingredient (API) manufacturer but a sophisticated global Contract Development and Manufacturing Organization (CDMO) and specialty pharma platform. The human health division is aggressively targeting high-margin CDMO revenues, with management guiding for 40% growth in innovator lifecycle management contracts in FY27.

The Animal Health division (operating under the Alivira brand) is executing a strategic pivot from low-margin production animal products to high-growth companion animal therapeutics. The companion animal market in Europe represents an addressable market of approximately $1 bn (excluding vaccines). This market is characterized by low insurance penetration (around 15%), which naturally drives volume toward affordable branded generic options as pet ownership increases. Unlike human generics, which face up to 95% price erosion upon loss of exclusivity, animal health generics typically experience a much shallower 30-40% price erosion,
thereby preserving long-term profitability and extending the lifecycle of the product portfolio. Capital allocation remains highly strategic, evidenced by the October 2026 acquisition of BioForLife Italia for an upfront consideration of EUR 15 mn. With reported CY25 sales of EUR 9 mn, this asset serves as a direct, high margin launchpad for Viyash's proprietary companion animal portfolio into Europe's lucrative veterinary clinic channels

Source: Sushil Finance Research, Company Research

KEY RISKS


1.**Regulatory & Quality Compliance Risk**: Viyash's investment thesis is highly levered to its flawless regulatory record across 10 USFDA-approved sites. The US generic pipeline hinges heavily on the Vizag and Taloja facilities. Any escalation of routine FDA observations into Official Action Indicated (OAI), Warning Letters, or Import alerts would instantly paralyze the high-margin US human and animal API revenue streams


2.**Raw Material Volatility & Freight Costs:** Despite achieving 85% backward integration, Viyash relies heavily on bulk solvents. Management acknowledged minor impacts from geopolitical freight disruptions and solvent price volatility in late FY26. Prolonged geopolitical shocks could squeeze gross margins if the company loses pricing power against large generic buyers.


3. Foreign Exchange Exposure: With manufacturing facilities in Turkey and Brazil, Viyash is exposed to severe emerging market currency volatility. Specifically, hyperinflationary accounting dynamics in Turkey represent an ongoing translational risk to reported INR revenues and earnings, necessitating rigorous, proactive FX hedging postures


Source: Sushil Finance Research, Company Research

BUSINESS OVERVIEW









Source: Sushil Finance Research, Company Research

PROFIT & LOSS STATEMENT **(Rs. cr)**

Y/E Mar.	FY26	FY27E	FY28E	FY29E
Revenue	**3,420.3**	**3,931.9**	**4,491.5**	**5,138.4**
Raw Material Cost	1,563	1,813	2,071	2,348
Employee Cost	565.5	629.1	718.6	822.1
Other Expenses	639.6	747.1	853.4	976.3
EBITDA	**652.5**	**743.1**	**848.9**	**991.7**
EBITDA Margin (%)	*19.1%*	*18.9%*	*18.9%*	*19.3%*
Depreciation	233.6	255.6	291.9	334.0
Finance Costs	69.2	78.6	89.8	92.5
Other Income	43.6	43.3	49.4	56.5
Profit before Tax	**349.0**	**452.2**	**516.5**	**621.7**
Tax Expense	124.4	113.0	129.1	155.4
Adjusted PAT	**224.7**	**339.1**	**387.4**	**466.3**
Net Margin (%)	*6.6%*	*8.6%*	*8.6%*	*9.1%*
Adjusted EPS	**4.0**	**7.8**	**8.9**	**10.7**

Source: Sushil Finance Research, Company Research

BALANCE SHEET STATEMENT

(Rs. cr)

Y/E Mar.	FY26	FY27E	FY28E	FY29E
PP&E (incl. CWIP)	1,132	1,210	1,298	1,399
Other Non-Current	1,242	1,261	1,293	1,329
Inventories	803	906	1,035	1,174
Trade Receivables	1,045	1,202	1,373	1,570
Cash and Bank Balances	270	363	474	612
Other Current Assets	136	138	141	143
Total Assets	**4,628**	**5,081**	**5,614**	**6,228**
Equity Share Capital	87	87	87	87
Reserves & Surplus	3,027	3,343	3,707	4,150
Borrowings	436	433	441	440
Other Non-Current Liabilities	266	289	320	348
Trade Payables	597	697	796	903
Other Current Liabilities	215	230	263	299
Total Liabilities	**4,628**	**5,081**	**5,614**	**6,228**

Source: Sushil Finance Research, Company Research

CASH FLOW STATEMENT

(Rs. cr)

Y/E Mar.	FY26	FY27E	FY28E	FY29E
PBT	349	452	517	622
Depreciation	234	256	292	334
Interest	69	79	90	92
CFO before Working Cap chg	652	786	898	1,048
Chg in Inventories	(121)	(103)	(129)	(139)
Chg in Trade Receivables	(239)	(156)	(171)	(198)
Chg in Trade Payables	108	100	99	107
Income tax paid	(124)	(113)	(129)	(155)
Chg in Other Adjustments	195	-	-	-
Cash Flow from Operations	**323**	**547**	**616**	**717**
Interest Paid	(69)	(79)	(90)	(92)
Dividend Paid	-	-	-	-
Other Adjustments	(70)	-	-	-
Cash Flow from Financing	**(124)**	**(77)**	**(70)**	**(84)**
Capital Expenditure	(290)	(333)	(380)	(435)
Other Adjustments	202	(23)	(23)	(23)
Cash Flow from Investing	**(85)**	**(376)**	**(435)**	**(495)**
Opening Cash	**140**	**256**	**349**	**460**
Total Cash Flow	**114**	**94**	**111**	**138**
Closing Cash	**255**	**349**	**460**	**598**

Source: Sushil Finance Research, Company Research


FINANCIAL RATIOS STATEMENT


Y/E Mar.	FY26	FY27E	FY28E	FY29E
Growth (%)				
Revenue	13.8%	15.0%	14.2%	14.4%
EBITDA	68.6%	13.9%	14.2%	16.8%
Net Profit	NM	51.0%	14.2%	20.4%
Profitability (%)				
EBITDA Margin	19.1%	18.9%	18.9%	19.3%
Net Profit Margin	6.6%	8.6%	8.6%	9.1%
ROCE	11.4%	12.2%	12.7%	13.6%
ROE	7.2%	9.9%	10.2%	11.0%
Per Share Data (Rs.)				
EPS	4	8	9	11
BVPS	72	79	87	97
Valuation (x)				
P/E	57.9	29.8	26.1	21.6
P/BV	3.2	2.9	2.7	2.4
EV/EBITDA	15.3	13.3	11.5	9.8
P/Sales	3.0	2.6	2.2	2.0
Turnover				
Inventory days	188	183	183	183
Debtor days	112	112	112	112
Creditor days	140	140	140	140
Gearing (x)				
D/E	0.04	0.04	0.04	0.04

Source: Sushil Finance Research, Company Research

MARKET INFORMATION









Source: Sushil Finance Research, Company Research

Rating Scale : This is a guide to the rating system used by our Institutional Research Team. Our rating system comprises of three rating categories.

Total Expected Return Matrix (Rating and Return)	BUY : Over 12%	HOLD : -12% to 12%	SELL : Below -12%

Disclaimer & Disclosures

https://www.sushilfinance.com/Disclaimer/research

https://www.sushilfinance.com/InvestorGrievances/researchanalystinvestorgrievancecell

This report has been furnished to you for your general information only and should not be reproduced, re-circulated, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of Sushil Financial Services Private Limited. This Research Report is meant solely for use by the original recipient to whom it is sent and is not for circulation. Any unauthorized use, disclosure or public dissemination or copying of information (either whole or partial) contained herein is prohibited.

This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice/offer for the purpose of purchase or sale of any securities mentioned herein. Past performance is not a guide for future performance, future returns are not guaranteed. Opinions expressed herein are subject to change without notice. Investor should rely on information/data arising out of their own investigations. The Sushil Equity Universe is marked as # and the fundamental reports are marked as ##.

Investors are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investor may realize losses on any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by us to be reliable. A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com Research Analyst views on Subject Company may vary based on Fundamental and Technical Research. Sushil Financial Services Private Limited or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. None of the directors, employees, affiliates or representatives of company shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages/loss etc whatsoever from the information/opinions/views contained in this Report and investors are requested to use the information contained at their risk.

Sushil Financial Services Private Limited (SFSPL) and its connected companies, and their respective Directors, Officers and employees or their relative, may have a long or short position in the subject companies mentioned in the report and it may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Reports based on technical and derivative analysis centre on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. SFPSL has different business segments/Divisions with independent research and maintains arm's length distance catering to different set of customers having various objectives, risk profiles, investment horizon, etc. and therefore may at times have different contrary views on stocks sector and markets. Research Report may differ between SFSPL's RAs on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold - SFSPL, its employees and associates responsible for any losses, damages of any type whatsoever.

This Report is not intended to be a complete statement or summary of the securities, market or developments referred to in this document. SFSPL or its affiliates or employees are under no obligation to update the information. SFSPL or its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report.

SFSPL or its affiliates and/or its employees/its associates or his relative does not have financial interest in the subject companies. SFSPL or its affiliates and/ or its employees/its associates or his relative may or may not have beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report. SFSPL/its Associates/ Research Analyst have not received any compensation from the subject company in the past twelve months. Further the subject company is/was not a client during twelve months preceding the date of distribution of the research report and the types of services provided. SFSPL or its research analyst has not served as an officer, director or employee of the subject company. SFSPL or its affiliates and/or its research analysts have not been engaged in market making activity for the subject company. SFSPL or its associates or its Research Analyst have not received any compensation or other benefits from the subject companies or third party in connection with the research report. SFSPL/its Associates/ Research Analyst/ his Relatives not have any other material conflict of interest at the time of publication of the research report.

SFSPL/its Associates/ Research Analyst have not managed or co-managed public offering of securities, have not received compensation for investment banking or merchant banking or brokerage services, have not received any compensation for product or services other than investment banking or merchant banking or brokerage services from the subject companies in the last twelve months. There is no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

Research Disclaimer: Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Sushil Financial Services Private Limited

Member : BSE / NSE - SEBI Regn. No. INZ000165135

Research Analyst – SEBI Registration No. INH000000867

Compliance officer / Grievance Officer : Mr. Suresh Nemani – Phone : +91 22-40935000 | Email : suresh.nemani@sushilfinance.com | Grievance Email - compliance@sushilfinance.com

Regd. Office : 12, Homji Street, Fort, Mumbai 400 001.

Phone: +91 22 40936000 Fax: +91 22 22665758 | Email : info@sushilfinance.com

Analyst Stock Ownership	No
Stock Recommended to Clients	Yes
Remuneration/Benefits received from company in 12 months	No
Merchant Banking Market Making activities / projects	No
Sushil Financial Services Pvt. Ltd and Group Companies Holding	No
Sushil Financial Services Pvt. Ltd and Group Directors Holding	No
Broking Relationship with the company covered	No